Julien Taı̈eb

Research interests

Publications

• Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2214963

• Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2308795

• Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment

  European Journal of Cancer · 2022 · 10.1016/j.ejca.2022.07.020

• Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.10.003

• Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.06.022

• Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30527-1

• Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1713709

• Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

  Annals of Oncology · 2018 · 10.1093/annonc/mdy264

• First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30457-6

• ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

  Annals of Oncology · 2016 · https://doi.org/10.1093/annonc/mdw235

• FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)00172-8

• SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer

  Journal of Clinical Oncology · 2016 · https://doi.org/10.1200/jco.2015.66.1181

• Prognostic Value ofBRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer

  JNCI Journal of the National Cancer Institute · 2016 · 10.1093/jnci/djw272

• VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors

  The Journal of Experimental Medicine · 2015 · https://doi.org/10.1084/jem.20140559

• Control of the Immune Response by Pro-Angiogenic Factors

  Frontiers in Oncology · 2014 · 10.3389/fonc.2014.00070

• Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(14)70227-x

• VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer

  Cancer Research · 2012 · 10.1158/0008-5472.can-12-2325

• Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy

  Cancer and Metastasis Reviews · 2011 · https://doi.org/10.1007/s10555-011-9281-4

• Dendritic Cell-Derived Exosomes Promote Natural Killer Cell Activation and Proliferation: A Role for NKG2D Ligands and IL-15Rα

  PLoS ONE · 2009 · 10.1371/journal.pone.0004942

• Identification of CD8 + CD25 + Foxp3 + suppressive T cells in colorectal cancer tissue

  Gut · 2008 · 10.1136/gut.2008.158824

• A novel dendritic cell subset involved in tumor immunosurveillance

  Nature Medicine · 2006 · 10.1038/nm1356

• CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner

  The Journal of Experimental Medicine · 2005 · 10.1084/jem.20051511

• Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial

  Journal of Clinical Oncology · 2005 · https://doi.org/10.1200/jco.2005.06.023

• Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell–dependent antitumor effects

  Journal of Clinical Investigation · 2004 · 10.1172/jci21102

• Exosomes as Potent Cell-Free Peptide-Based Vaccine. II. Exosomes in CpG Adjuvants Efficiently Prime Naive Tc1 Lymphocytes Leading to Tumor Rejection

  The Journal of Immunology · 2004 · 10.4049/jimmunol.172.4.2137

Current projects

No projects listed.